Skip to main content

Table 4 Evolution of biomarkers during the study compared to pretreatment (basal) value

From: A randomized phase II study of capecitabine-based chemoradiation with or without bevacizumab in resectable locally advanced rectal cancer: clinical and biological features

 

Arm A

Arm B

(BVZ + CAP + RT)

(CAP + RT)

 

VEGF

VEGFR-2

Ang-2

MVD b

VEGF

VEGFR-2

Ang-2

MVD b

Basal

        

 n

18

18

18

12

23

23

23

18

 Median

56

9056

2424

14

85

9282

3609

14

p

NA

NA

NA

NA

NA

NA

NA

NA

D15a

        

 n

18

18

18

12

23

23

23

18

 Median

13

7

22

8

40

4

16

34

p

0.19

0.18

0.04

0.73

0.11

0.33

0.11

0.03

D57a

        

 n

14

14

13

NA

17

17

17

NA

 Median

55

7

16

NA

13

2

20

NA

p

0.03

0.20

0.20

NA

0.71

0.86

0.01

NA

  1. Abbreviations: IQR interquartile range, VEGF vascular endothelial growth factor, VEGFR-2 circulating soluble VEGF receptor 2, Ang-2 angiopoietin-2.
  2. aPercent difference (%) = [(Later value- Basal value)/Basal value] × 100.
  3. bTissue samples (baseline and at surgery).